I
Imara
Biotech & Life Sciences · Boston, United States · Founded 2016 · IPO 2020
Dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies MoreLess
Imara Inc. is a biopharmaceutical company focused on developing innovative therapies for patients suffering from rare genetic blood disorders, specifically sickle cell disease and beta thalassemia. The company operates in the healthcare sector, targeting a niche market of individuals affected by these hemoglobinopathies. Imara's core product, IMR 687, is a highly selective, potent small molecule inhibitor of PDE9, designed to be an oral, once-daily treatment that potentially modifies the disease. The business model revolves around the research, development, and commercialization of this therapeutic candidate, aiming to improve patient outcomes and quality of life. Revenue is generated through the sale of IMR 687, once approved, and potentially through partnerships and licensing agreements with other pharmaceutical companies. Imara serves patients, healthcare providers, and broader communities impacted by these rare diseases. The company is also involved in initiatives like the Real Impact Grants Program to support affected individuals and has been recognized by its inclusion in the U.S. Small Cap Russell Index.
Keywords: biopharmaceutical, sickle cell disease, beta thalassemia, IMR 687, PDE9 inhibitor, rare diseases, hemoglobinopathies, healthcare, therapeutic development, Real Impact Grants.
Company overview
Imara company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2016
- Headquarters
- Boston, United States
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 70.0
Valuation & funding
Imara funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| MERGER✓Other financing | Feb 2023 | — | — | Enliven Therapeutics | ↗ |
| POST IPO EQUITYOther financing | Jul 2021 | $50M | — | Undisclosed | — |
| IPO✓Exit | Mar 2020 | $0 | — | Undisclosed | — |
| SERIES B✓Equity / VC | Mar 2019 | $63M | $252M | Lundbeckfonden Ventures · NEA · Bay City Capital · OrbiMed | — |
| SERIES A✓Equity / VC | Apr 2016 | $31M | $124M | Alexandria Venture Investments · Lundbeckfonden Ventures · NEA · Bay City Capital | — |
| SEED✓Equity / VC | Jan 2016 | NEA · Bay City Capital · Pfizer | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 11 |
| 2025 | 20 |
| 2024 | 20 |
| 2023 | 20 |
| 2022 | 20 |
| 2021 | 42 |
| 2020 | 28 |
Growth signals
Imara website traffic
Latest recorded traffic for Imara is 1.1K monthly website visits, up 223.5% over the last three months. Imara's team declined 50% over the past year.
Comparisons
Imara compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Imara's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Imara has talent and traffic
In the news
Latest news about Imara
Recent press, funding announcements, and product moves mentioning Imara — open to read from the original sources.
Market sentiment
What the market is saying about Imara
An AI-synthesized read of the highest-engagement posts about Imara on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Imara’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.